solver.press

Agentic retrieval policies in biomedical multi-hop reasoning (SSE-Bio) can be formally verified via probabilistic Datalog to reduce hallucinated protein-disease links by 40%, using attention-derived co-expression signals from ELISA as grounding constraints.

Computer ScienceSep 13, 2026Evaluation Score: 62%

Agentic retrieval policies in biomedical multi-hop reasoning (SSE-Bio) can be formally verified via probabilistic Datalog to reduce hallucinated protein-disease links by 40%, using attention-derived co-expression signals from ELISA as grounding constraints.

Adversarial Debate Score

43% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Gemini: 5/10 Strengths: The hypothesis is highly falsifiable, logically sound, and directly supported by the ELISA paper's integration of single-cell RNA-seq grounding constraints. Furthermore, it avoids all refuted hardware and ligand-binding dead ends from the owner's experiments, building in...
Mistral: The hypothesis is falsifiable and aligns with validated grounding constraints (ELISA co-expression signals, UCB acquisition), but its 40% hallucination-reduction claim lacks direct empirical support in the provided experiments, and probabilistic Datalog verification remains untested in the owner’...
ChatGPT: The hypothesis is falsifiable, but neither the excerpts nor the owner’s validated experiments substantiate probabilistic-Datalog verification, the specific 40% reduction, or attention-derived ELISA co-expression constraints. It also conflates attention with validated biological association and po...
Claude: The hypothesis fuses four largely orthogonal technical claims — probabilistic Datalog verification of agentic retrieval, SSE-Bio hallucination reduction, a precise 40% quantitative target, and ELISA attention-derived co-expression signals as grounding constraints — without any mechanistic bri...

Supporting Research Papers

Literature Assessment

📖 Literature-assessed (LLM)· literature_meta

An LLM's reading of the literature — not computational verification.

Probabilistic Datalog shows promise but lacks definitive evidence for hallucination reduction.

Method: literature_meta · Result: inconclusive

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Experimental Validation Package

This discovery has a Claude-generated validation package with a full experimental design.

Precise Hypothesis

When an agentic multi-hop biomedical reasoning system (SSE-Bio architecture) generates protein-disease link predictions, wrapping its retrieval policy in a probabilistic Datalog verification layer — constrained by attention-derived co-expression signals empirically grounded in ELISA measurements — reduces the rate of hallucinated (i.e., unsupported by any verifiable evidence chain) protein-disease link predictions by ≥40% relative to an unconstrained baseline agent, measured on a held-out benchmark of protein-disease claims with independently adjudicated ground truth (true/false/unknown), at equal or better recall on true positive links (recall degradation ≤5 percentage points).

Operationalized as two falsifiable sub-claims:

  • H1 (Precision): Hallucination rate (FP / (FP+TP), where "hallucinated" = claim not entailed by any verified evidence path) drops from baseline rate B to ≤0.60·B.
  • H2 (Non-degradation): True positive recall on the same benchmark does not drop by more than 5 points absolute vs. baseline.

The MS transcriptomics targets (DNMT1, ZNF740, CTSS, FGF2, SLCO2B1 and their claimed network edges to STAT3, IFNG, CSF1R/PTPRC, TREM2) serve as one of ≥3 real-world evaluation domains — used specifically because the underlying analysis is unpublished, internally scored, and contains at least one already-identified error (the superseded 36,966-cell figure), making it a natural adversarial test case for hallucination detection.


Disproof criteria:

The hypothesis is disproved if any of:

  1. Relative hallucination reduction is <40% (point estimate) OR the 95% CI lower bound excludes 40% reduction across ≥2 of 3 evaluation domains.
  2. Recall on true protein-disease links drops by >5 percentage points in the verified condition vs. baseline.
  3. The probabilistic Datalog verification layer fails to terminate or times out (>60s/query) on >10% of benchmark queries, making it operationally non-viable regardless of accuracy.
  4. Hallucination reduction is observed but is statistically indistinguishable from reduction achieved by a simpler baseline (e.g., a static hard-coded whitelist filter or a non-probabilistic rule-based grounding check) — i.e., the probabilistic and Datalog-specific machinery adds no measurable value over ablations.
  5. ELISA-derived co-expression grounding shows no significant difference in downstream hallucination rate vs. using RNA-seq-only co-expression as the grounding signal (would falsify the specific claim that ELISA grounding is necessary/beneficial vs. cheaper transcriptomic grounding).

Spine & Adversarial ReadReady for validation

“This hypothesis tests whether adding a probabilistic-Datalog verification layer, constrained by ELISA-grounded co-expression signals, to an agentic multi-hop biomedical reasoning system reduces its rate of hallucinated protein-disease link predictions by at least 40% without materially reducing true-positive recall. ---”

Experimental Protocol

Design: 2×2 factorial, within-benchmark, repeated-measures comparison.

  • Factor A: Verification layer (probabilistic Datalog ON vs. OFF)
  • Factor B: Grounding signal source (ELISA-derived vs. RNA-seq-only vs. none)

Minimum viable test (MVT):

  1. Build a 150-claim benchmark of protein-disease link assertions (50 true positive, 50 true negative/refuted, 50 currently-unknown/contested) drawn from: (a) the MS target hierarchy above (DNMT1–STAT3, ZNF740–IFNG/BRD2/3/4, CTSS–CSF1R/PTPRC, FGF2, SLCO2B1–TREM2), (b) OpenTargets high-confidence associations for 2 other diseases (rheumatoid arthritis, Alzheimer's) as generalization controls, (c) a synthetic "trap set" of 20 plausible-sounding but fabricated links (e.g., invented gene-disease pairs matching real gene/disease name distributions) to directly probe hallucination susceptibility.
  2. Run SSE-Bio baseline agent (no verification) on all 150 claims, 5 runs/claim (temperature sampling) → baseline hallucination rate B.
  3. Run SSE-Bio + probabilistic Datalog verification (ELISA-grounded) on identical claims/seeds → treatment hallucination rate T.
  4. Run 2 ablations: (i) Datalog verification with RNA-seq-only grounding, (ii) simple rule-based whitelist filter (no probabilistic logic) — to isolate which component drives any observed effect.
  5. Blind adjudication of all outputs by 2 independent biomedical curators against OpenTargets/STRING/CTD ground truth + manual literature check for contested claims; Cohen's κ reported.

Required datasets:
  • Benchmark claims corpus: 150-claim curated set (constructed above); OpenTargets Platform (v24+) and DisGeNET for ground-truth adjudication; CTD for corroboration.
  • KG substrate for retrieval: STRING v12 (physical + functional edges), the 50-gene MS seed set already used in Phase 4 of the internal pipeline, GeneCards.
  • Grounding signal data: ELISA co-expression panel — either newly generated (see below) or a proxy public dataset (e.g., Olink/SomaScan plasma proteomics from public MS cohorts) if primary ELISA is unavailable within timeline; RNA-seq comparator: GSE193770, GSE138614 (already in use internally), GTEx v10.
  • Models: SSE-Bio agent implementation (assumed existing per discovery; if not, a comparable ReAct/multi-hop LLM agent scaffold, e.g., GPT-4o/Claude/Llama-3-70B backbone + KG retrieval tools).
  • Verification engine: ProbLog or DeepProbLog (open-source), or a custom probabilistic Datalog implementation (e.g., built on Souffle + weighted model counting).
  • Compute environment: as specified below.
  • Code base for MS substrate: github.com/tradingjohn/ms-transcriptomics-carrim (reused for domain-specific claim generation and to test whether the verifier catches the known 36,966-cell error as a positive control for hallucination detection).

Success:
  • Primary: Relative hallucination reduction ≥40% (point estimate), 95% CI lower bound >25%, McNemar p<0.01, replicated in ≥2 of 3 domains (MS, RA, Alzheimer's).
  • Secondary: Recall degradation ≤5 points absolute.
  • Mechanistic: Verified condition significantly outperforms whitelist-filter ablation (p<0.05) — confirms probabilistic Datalog adds value beyond trivial filtering.
  • Grounding specificity: ELISA-grounded condition outperforms RNA-seq-only grounding by a nontrivial, statistically significant margin (else grounding claim narrows to "any orthogonal signal works," not specifically ELISA).
  • Operational: Median query latency <10s, timeout rate <5%.
  • Calibration: Brier score on contested/unknown subset improves by ≥20% vs. baseline.

Failure:
  • Relative reduction <40% or CI includes 25% or lower.
  • Recall drop >5 points.
  • No significant difference vs. whitelist-filter ablation (probabilistic machinery unjustified).
  • No significant difference between ELISA and RNA-seq grounding (headline "ELISA constraint" claim unsupported).
  • Timeout/non-termination rate >10%.
  • Effect fails to replicate outside the MS domain (suggests overfitting to the specific internal dataset/known errors it was tuned against).

180

GPU hours

45d

Time to result

$18,000

Min cost

$95,000

Full cost

ROI Projection

Commercial:

Directly applicable as a middleware layer for any organization running LLM/agentic pipelines over biomedical KGs (target discovery teams, CRO informatics units, biomedical literature-mining SaaS). Defensible IP surface: the specific combination of probabilistic Datalog + attention-derived + ELISA-grounded constraints. Addressable market includes computational drug discovery platforms (comparable tools in this space have attracted enterprise contracts in the $500K–$5M/year range for validated "trustworthy AI" layers). Secondary value: reusable as an internal QC gate for the MS transcriptomics pipeline itself, directly catching errors like the already-identified 36,966-cell mispooling.


Prerequisites

These must be validated before this hypothesis can be confirmed:

  • MS-transcriptomics-CARRIM-target-hierarchy-internal-2026-05-30
  • SSE-Bio-agent-architecture-spec
  • probabilistic-Datalog-engine-selection-benchmark

Implementation Sketch

# 1. Benchmark construction
claims = build_benchmark(
    sources=[MS_target_hierarchy, OpenTargets_RA, OpenTargets_Alzheimers, synthetic_traps],
    n_true=50, n_false=50, n_contested=50
)
ground_truth = adjudicate(claims, curators=2, arbiter=1)

# 2. Grounding signal construction
elisa_grounding = build_coexpression_graph(elisa_panel_data, method="attention_derived_weighting")
rnaseq_grounding = build_coexpression_graph(GSE193770, GSE138614, method="attention_derived_weighting")

# 3. Probabilistic Datalog verification layer
rules = """
0.0::link(P,D) :- true.
w1::link(P,D) :- coexpressed(P,G,W), W > theta1.
w2::link(P,D) :- network_proximity(G,Seed,S), S < theta2.
verified(P,D) :- link(P,D), evidence_chain_length(P,D,L), L =< 4.
"""
verifier = ProbLogEngine(rules, grounding=elisa_grounding)

# 4. Agent runs
for condition in [baseline, verified_elisa, verified_rnaseq, whitelist_filter]:
    for claim in claims:
        for seed in range(5):
            output = SSE_Bio_agent.run(claim, verifier=condition, seed=seed)
            log(output.prediction, output.evidence_chain, output.confidence)

# 5. Scoring
hallucination_rate = FP / (FP + TP)   # per condition, per domain
recall = TP / (TP + FN)
mcnemar_test(baseline_outputs, verified_outputs)
bootstrap_ci(relative_reduction, n=10000)

Abort checkpoints:
  1. Day 7: If benchmark inter-annotator κ<0.5, halt and revise adjudication protocol before any agent runs (unreliable ground truth invalidates everything downstream).
  2. Day 14: If Datalog engine timeout rate on a 20-claim pilot subset exceeds 20%, halt and re-scope KG subgraph size or switch engine before full-scale runs.
  3. Day 21 (MVT checkpoint): If MS-domain-only point estimate for relative hallucination reduction is <20% (i.e., roughly half the target effect), consider aborting full 3-domain expansion — unlikely to reach significance at planned scale.
  4. Day 35: If verified condition does not beat whitelist-filter ablation at p<0.10 on interim analysis, flag for likely failure on Success Criterion "mechanistic" — decide whether to continue to full sample or pivot framing.

Source

AegisMind Research
Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started